ibrutinib,
PCI 32765,
PCI-32765,
PCI32765,
Ibrutinib,
936563-96-1,
PCI-32765,
IMBRUVICA,
PCI-32765 (Ibrutinib),
PCI 32765,
Ibrutinib (PCI-32765),
UNII-1X70OSD4VX,
CRA-032765,
1X70OSD4VX,
(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,
CHEBI:76612,
PCI32765,
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one,
A1-01649,
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one,
1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one,
2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-,
Ibrutinib [USAN:INN],
ibrutinibum,
JNJ 02,
Imbruvica (TN),
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one,
2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-,
Pc-32765,
CRA 032765,
PCI-32765-00,
Ibrutinib (JAN/USAN),
Ibrutinib/PCI-32765,
Ibrutinib (PCI32765),
Ibrutinib(PCI-32765),
PCI-32765(Ibrutinib),
MLS006010041,
SCHEMBL201859,
GTPL6912,
CHEMBL1873475,
HSDB 8260,
EX-A066,
XYFPWWZEPKGCCK-GOSISDBHSA-N,
AMX10219,
AOB87789,
KS-000002KE,
ABP000965,
BDBM50357312,
MFCD20261150,
ZINC35328014,
AKOS022185476,
ACN-030256,
AN-1333,
DB09053,
EBD2165770,
EX-5960,
KIN0000174,
QC-4573,
SB14736,
NCGC00187912-01,
NCGC00187912-02,
NCGC00187912-03,
NCGC00187912-12,
AC-26942,
AJ-91306,
HY-10997,
SC-96633,
SMR004701213,
AB0008168,
AX8254580,
FT-0696693,
SW218096-2,
X7513,
D10223,
S-7810,
J-523872,
(R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one,
1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one1-[(3R)-3-[4-AMino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyriMidin-1-yl],
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-2-propen-1-one,
1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one,
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]prop-2-en-1-one,
IbrutinibCI-32765mbruvica(R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,
piperidin-1-yl]prop-2-en-1-one1-{3-[4-AMino-3-(4-phenoxy-phenyl)-pyrazolo[3,4-d]pyriMidin-1-yl]-piperidin-1-yl}-propenone,
Ibrutinib [USAN],
D09KTS,
Ibrutinib (BTK inhibitor),
C25H24N6O2,
C25-H24-N6-O2,
CS-0015,
A3001,
A11020,
C551803,
(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,
1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one,